Successful gene therapy of mice with congenital erythropoietic porphyria;Succès de la thérapie génique d'un modèle murin de porphyrie érythropoïétique congénitale

Medecine/Sciences

Volumn 24, Issue 6-7, 2008, Pages 615-619

  De Verneuil, Hubert ^a   Robert Richard, Elodie ^a   Ged, Cécile ^a   Mazurier, Frédéric ^a   Richard, Emmanuel ^a   Moreau Gaudry, François ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; LENTIVIRUS VECTOR; UROPORPHYRINOGEN III SYNTHASE;

BONE MARROW TRANSPLANTATION; CELL SURVIVAL; CONGENITAL ERYTHROPOIETIC PORPHYRIA; ENZYME ACTIVITY; ERYTHROCYTE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NONHUMAN; REVIEW; STEM CELL GENE THERAPY;

LENTIVIRUS; MURINAE; MUS;

EID: 47749100857     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20082467615     Document Type: Review

References (25)

1. De Verneuil H, Ged C, Moreau-Gaudry F, et al. Les porphyries héréditaires : de la pathologie moléculaire à la thérapie génique. Med Sci (Paris) 1995 ; 11 : 873-8.
2. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis : X-linked sideroblastic anemia and the porphyrias. In : Scriver CR, Beaudet AL, Sly WS, Valle D, eds. New York : McGraw Hill, 2001 : 2991-3062.
3. De Verneuil H, Moreau-Gaudry F, Ged C. Congenital erythropoietic porphyria. In : Kadish KM, Smith KV, Guilard R, eds. The porphyria handbook. Amsterdam : Academic Press-Elsevier Science, 2003 : 43-66.
4. Dupuis-Girod S, Akkari V, Ged C, et al. Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Gunther disease). Eur J Pediatr 2005 ; 164 : 104-7.
5. Phillips JD, Steensma DP, Pulsipher MA, et al. Congenital erythropoietic porphyria due to a mutation in GATA1 : the first trans-acting mutation causative for a human porphyria. Blood 2007 ; 109 : 2618-21.
6. Taibjee SM, Stevenson OE, Abdullah A, et al. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria : a treatment dilemma. Br J Dermatol 2007 ; 156 : 567-71.
7. Faraci M, Morreale G, Boeri E, et al. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. Pediatr Transplant 2008 ; 12 : 117-20.
8. Ged C, Mendez M, Robert E, et al. A knock-in mouse model of congenital erythropoietic porphyria. Genomics 2006 ; 87 : 84-92.
9. Robert-Richard E, Moreau-Gaudry F, Lalanne M, et al. Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. Am J Hum Genet 2008 ; 82 : 113-24.
10. Pawliuk R, Bachelot T, Wise RJ, et al. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999 ; 5 : 768-73.
11. Fontanellas A, Mendez M, Mazurier F, et al. Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Gene Ther 2001 ; 8 : 618-26.
12. Richard E, Mendez M, Mazurier F, et al. Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther 2001 ; 4 : 331-8.
13. + cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria. Mol Ther 2001 ; 3 : 411-7.
14. Moreau-Gaudry F, Mazurier F, Bensidhoum M, et al. Metabolic correction of congenital erythropoietic porphyria by retrovirus-mediated gene transfer into Epstein-Barr virus-transformed B-cell lines. Blood 1995 ; 85 : 1449-53.
15. Géronimi F, Richard E, Lamrissi-Garcia I, et al. Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells. J Mol Med 2003 ; 81 : 310-20.
16. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003 ; 302 : 415-9 et 568.
17. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Thérapie génique du déficit immunitaire combiné sévère lié à l'X : efficacité et complications. Med Sci (Paris) 2004 ; 20 : 115-7.
18. Wilson JM. Adverse events in gene transfer trials and an agenda for the new year. Hum Gene Ther 2008 ; 19 : 1-2.
19. Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells : the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Mol Ther 2007 ; 15 : 445-56.
20. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006 ; 103 : 17372-7.
21. + hematopoietic cells. Blood 2007 ; 110 : 1770-8.
22. Robert-Richard E, Richard E, Malik P, et al. Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther 2007 ; 15 : 173-82.
23. Arumugam PI, Scholes J, Perelman N, et al. Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther 2007 ; 15 : 1863-71.
24. Schambach A, Bohne J, Baum C, et al. Woodchuck hepatitis virus posttranscriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 2006 ; 13 : 641-5.
25. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Thérapie génique du déficit immunitaire combiné sévère lié à l'X. Med Sci (Paris) 2004 ; 20 : 115-7.